FIELD: chemistry.
SUBSTANCE: present invention relates to a compound of formula (I):
,
optionally linked with an effector moiety, where the effector moiety includes an effector that is a diagnostically active nuclide or a therapeutically active nuclide.
EFFECT: obtaining novel compounds of formula (I), as well as pharmaceutical compositions based thereon, which inhibit the activity of the NTR1 ligand.
26 cl, 30 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| A CONJUGATE CONTAINING A NEUROTENSIN RECEPTOR LIGAND AND ITS APPLICATION | 2015 |
|
RU2743781C2 |
| COMPLEX CONTAINING A PSMA-TARGETING COMPOUND BOUND TO A LEAD OR THORIUM RADIONUCLIDE | 2018 |
|
RU2795398C2 |
| STABLE CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | 2020 |
|
RU2839656C1 |
| BOMBESIN ANALOGUE PEPTIDE ANTAGONIST CONJUGATES | 2009 |
|
RU2523531C2 |
| DIAGNOSIS, TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH THE NEUROTENSIN RECEPTOR | 2017 |
|
RU2796538C2 |
| PARAMINOHYPURIC ACID (PAH) AS A KIDNEY PROTECTOR | 2020 |
|
RU2804349C2 |
| NOVEL RADIOIMMUNOCONJUGATES AND THEIR APPLICATIONS | 2011 |
|
RU2560587C9 |
| NOVEL RADIOIMMUNOCONJUGATES AND USE THEREOF | 2011 |
|
RU2664475C1 |
| NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
| RADIOLABELLED GRPR ANTAGONIST FOR USE AS THERAPEUTIC AND DIAGNOSTIC AGENT | 2020 |
|
RU2839888C1 |
